Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Conflict of interest
- EAU guidelines 2022
- Definition of “uncomplicated” cystitis
- UTI – a social burden
- Diagnostics
- Aetiology of uncomplicated UTI
- Clinical definitions of uncomplicated UTI according to FDA and EMA
- Primary analysis of uncomplicated UTI
- Microbiological diagnostics of AUC
- Acute Cystitis Symptom Score
- Acute Cystitis Symptom Score: questionnaire
- “Typical” symptoms of acute cystitis
- Mean (±SD) scores of ‘typical’ symptoms
- Youden’s index of the six ACSS typical symptoms
- Receiver operating characteristic (ROC) curves for the six individual typical symptoms
- The 2017 Update of the German Clinical Guidelines
- Antimicrobial resistance of uropathogens is increasing worldwide
- 3rd generation cephalosporin-resistant Enterobacteriaceae
- Fluoroquinolone-resistant gram-negative bacilli
- Carbapenem-resistant Enterobacteriaceae
- EAU guidelines of acute uncomplicated cystitis 2023
- Acute uncomplicated cystitis
- Collateral damage
- Antibiotics Side Effects: Fluoroquinolones
- Trimethoprim intervention study
- Should we treat bacteriuria?
- Asymptomatic bacteriuria/candiduria: antibiotic treatment
- Antibiotic therapy in diabetes with asymptomatic bacteriuria
- Asymptomatic bacteriuria (ABU) in patients with recurrent cystitis
- ABU protects against UTI
- Antibiotic treatment
- Ibuprofen versus fosfomycin for uncomplicated urinary tract infection
- Ibuprofen versus fosfomycin: scoring system
- Ibuprofen versus fosfomycin: results
- Recurrent UTI and complications after symptomatic versus antibiotic treatment
- Ibuprofen versus pivmecillinam for uncomplicated UTI
- Ibuprofen versus pivmecillinam: patients who felt cured
- Ibuprofen versus pivmecillinam: mean symptom score
- Ibuprofen versus pivmecillinam: conclusion
- The 2017 update of the German clinical guideline
- Is phytotherapy an alternative for treatment and prophylaxis of uncomplicated UTI?
- Efficacy and safety of BNO 1045
- Influence on the microbiome under BNO 2103 therapy compared to antibiotics
- BNO 1045 in Phase III clinical trial
- Canephron® N for uncomplicated lower urinary tract infections of women (Can UTI-7)
- Study design
- Protocol
- Results: non-inferiority of Canephron® N versus FT
- Results: comparison of mean sum-scores of the ACSS-typical symptoms
- Results: Acute Cystitis Symptom Score-Quality of Life
- Adverse events/safety
- Cases of pyelonephritis
- Cytokine analysis in urine: Can-UTI 7 study: IL-6
- Cytokine analysis in urine: Can-UTI 7 study: IL-8
- Can UTI-7 – summary
- Canephron®: retrospective database analysis
- Retrospective database analysis: results (1)
- Retrospective database analysis: results (2)
- Retrospective database analysis: results
- New guidelines needed for testing drugs indicated for treatment of uncomplicated UTI
- Clinical validation of American English ACSS
- Clinical validation of American English ACSS: summary score over time
- Clinical validation of the Turkish ACSS
Topics Covered
- Clinical definitions of uncomplicated UTI
- Analysis and diagnosis of uncomplicated UTI
- Acute Cystitis Symptom Score
- Antibiotic treatment and antibiotic resistance
- Ibuprofen versus fosfomycin for uncomplicated UTI
- Ibuprofen versus pivmecillinam for uncomplicated UTI
- Efficacy and safety of BNO 1045
- Canephron® N for uncomplicated UTIs
Links
Categories:
Therapeutic Areas:
External Links
Talk Citation
Naber, K.G. (2023, November 30). Novel treatment and prophylaxis of uncomplicated urinary tract infections 1 [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 23, 2024, from https://doi.org/10.69645/XGID2250.Export Citation (RIS)
Publication History
Financial Disclosures
- Adamed Pharma: Consultant; Bionorica: Consultant, Scientific Presentations and Publications; Bio Merieux: Scientific Presentations; GlaxoSmithKline: Consultant; Ingenion Medical: Consultation; Janssen Pharmaceutica: Consultant; OM Pharma: Consultant, Scientific Presentations and Publications; MIP/Rosen Pharma: Consultant, Scientific Presentations and Publications.
Novel treatment and prophylaxis of uncomplicated urinary tract infections 1
Published on November 30, 2023
39 min
A selection of talks on Gastroenterology & Nephrology
Transcript
Please wait while the transcript is being prepared...
0:00
Welcome to our meeting today.
We will talk about
novel treatment and
prophylaxis of uncomplicated
urinary attract infections.
0:12
My conflict of interest, of
course, are companies who
also are involved in
urinary attract infections
I'm consulting,
0:22
on the next slide, you can see
how urinary attract infection is
divided according to the
EAU Guidelines 2022.
You see cystitis,
pyelonephritis,
and recurrent UTI can be
either uncomplicated
UTI or complicated UTI,
so we have to differentiate between
them. Then, catheter associated UTI,
UTI in men, and urosepsis are
always complicated UTI
with a much higher risk.
0:53
The next slide, the definition
of EAU guidelines of
2023 uncomplicated cystitis is
defined as acute, sporadic,
or recurrent cystitis limited
to non-pregnant women with
no known relevant anatomical
and functional abnormalities
within the urinary
tract or comorbidities.
1:16
On the next slide,
you can see that UTI is
mostly uncomplicated.
UTI, mostly in women and
40 percent of women will have
at least one infection and
11 percent will have
infections every year and
20 to 30 percent of women
will have so called
recurrent UTI,
which means three episodes
per year, or 2-6 months.
After intercourse,
there's a high risk of
UTI, about 30 percent.
Hide